Genecast develops cancer diagnostic products. It offers a cancer screening kit that helps to diagnose and monitor cancer through liquid biopsy using its Allele-Discriminating Priming System (ADPS) technology. The company was founded in 2016 and is based in Seoul, South Korea.
Genecast's Product Videos
Genecast's Products & Differentiators
ADPS™ EGFR Mutation Test Kit v1
The ADPS™ EGFR Mutation Test kit v1 is a real–time PCR assay for qualitative detection of 44 somatic mutations in exons 18-21 of the EGFR gene. CE-IVD approved.
Latest Genecast News
Jun 14, 2021
Save for later NEW YORK – Genecast said on Monday that it will launch a clinical trial to assess whether its qPCR-based liquid biopsy test can detect EGFR mutations in early-stage non-small cell lung cancer, or NSCLC, patients. The Seoul, South Korea-based diagnostics firm developed its liquid biopsy assay using allele-discriminating priming system, or ADPS, technology, which it says allows for simpler and faster diagnostics than other liquid biopsy technologies due to its high detection sensitivity. In a clinical trial conducted at the Samsung Medical Center, the firm will now evaluate how well the test reflects the results of tumor-based EGFR mutation testing for patients with stage 1B to 3A NSCLC. Should the trial validate the ADPS liquid biopsy's ability to pick up somatic EGFR mutations in this early-stage NSCLC population, Genecast hopes it will become a useful tool to guide anti-EGFR treatment decisions. Specifically, detecting EGFR mutations at the onset for early-stage NSCLC could identify patients eligible for adjuvant or neoadjuvant EGFR inhibitors such as osimertinib (AstraZeneca's Tagrisso), which has recently received regulatory approval in multiple countries — including the US and China — for early-stage NSCLC following surgical resection. AstraZeneca is also evaluating neoadjuvant osimertinib — that is, administering the therapy prior to surgical resection — in a Phase III clinical trial for EGFR-mutated early-stage NSCLC. Neoadjuvant treatment with an EGFR TKI necessitates EGFR mutation detection prior to surgery, which, for early-stage patients without distant metastases, is much more feasible via blood-based diagnostics than tissue biopsy. "With the recent FDA approval of osimertinib as an adjuvant therapy for early-stage NSCLC, the early diagnosis of this cancer using liquid biopsies is receiving attention again," Byungchul Lee, Genecast's chief technical officer, said in a statement. "If liquid biopsies can diagnose not only metastatic lung cancer, but also operable early-stage lung cancer, then they are likely to improve the survival rates of NSCLC patients."
Genecast Frequently Asked Questions (FAQ)
When was Genecast founded?
Genecast was founded in 2016.
Where is Genecast's headquarters?
Genecast's headquarters is located at 66 Chungmin-ro, Songpa-gu, Seoul.
What is Genecast's latest funding round?
Genecast's latest funding round is Series C.
How much did Genecast raise?
Genecast raised a total of $21.5M.
Who are the investors of Genecast?
Investors of Genecast include Access Biotechnology, Partners Investment, CJ Investment, P&P Investment, DK&D and 12 more.
Who are Genecast's competitors?
Competitors of Genecast include Guardant Health and 4 more.
What products does Genecast offer?
Genecast's products include ADPS™ EGFR Mutation Test Kit v1 and 4 more.
Who are Genecast's customers?
Customers of Genecast include C&J Med and GENVIA.
Compare Genecast to Competitors
Strata Oncology operates as a precision oncology company. The company offers services that integrate molecular profiling, decision support, and clinical trial participation into routine practice, providing care for cancer patients. Strata Oncology primarily serves healthcare providers, health systems, biopharma, and patients. It was founded in 2015 and is based in Ann Arbor, Michigan.
OncoHost is a technology company focused on precision oncology. The company's main service is its proprietary platform, PROphet®, which uses artificial intelligence and plasma proteomic profiling to predict the clinical benefit from anti-PD-1/PD-L1 treatment for cancer patients, providing actionable clinical insights and optimal therapy choices. OncoHost primarily serves the healthcare industry, specifically the oncology sector. It was founded in 2017 and is based in Binyamina, Israel.
Perthera operates as a healthcare artificial intelligence company focusing on advancing precision medicine in the oncology sector. The company offers an artificial intelligence (AI) enabled platform utilizing patient history and multi-omic testing results to match cancer patients with ranked therapy options, and accelerates clinical and therapeutic innovation. It was formerly known as Personalized Cancer Therapy. It primarily serves the healthcare industry in the oncology sector. It was founded in 2012 and is based in McLean, Virginia.
Genomic Expression is a company focused on improving healthcare delivery and cancer treatment effectiveness through RNA sequencing in the biotechnology industry. The company's main service is the OneRNA™ test, which sequences RNA and links it to approved therapies and clinical trials, with the aim of detecting diseases, monitoring health, and aiding in the design of next-generation cures. The company primarily serves the healthcare industry. It was founded in 2009 and is based in New York, New York.
First Ascent Biomedical provides health care solutions. It provides a software as a medical device (SaMD) service in a software as a service (SaaS) model that delivers artificial intelligence (AI) driven patient-specific cancer treatment plans in 3-4 weeks. It offers drug Selection, drug testing, deoxyribonucleic acid (DNA), ribonucleic acid (RNA) sequencing, and personalized cancer treatment plans. It was founded in 2018 and is based in Beaverton, Oregon.
Cofactor Genomics develops a diagnostics platform helping to predict the patient's response to immunotherapy. It offers precision medicine to immunotherapy using ribonucleic acid (RNA)-expression models. The company was founded in 2008 and is based in San Francisco, California.